GENE ONLINE|News &
Opinion
Blog

USFDA
Sun Pharma Temporarily Pauses Shipments from Mohali Following FDA’s Mandate for Corrective Actions
2023-04-24
First Treatment Targeting ALS Genetic Cause Could be a Reality with FDA Approval
2022-07-27
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
Amylyx’s New ALS Drug Review Impeded as FDA Members Disagreed with Clinical Trial Results
2022-04-04
FDA Announces Draft Guidances on Genome Editing and CAR T Cell Therapy
2022-03-25
Remdesivir Cleared for Treating Non-Hospitalized COVID-19 Patients
2022-01-24
FDA Places Clinical Hold on Kura Oncology’s Acute Myeloid Leukemia Therapeutic
2021-11-25
Takeda’s Livtencity Bags FDA Approval for the Treatment of Post-Transplant Infection
2021-11-24
FDA Approves Aadi Bioscience’s First Product to Treat Rare Cancer
2021-11-23
FDA Grants Priority Review for bluebird bio’s β-Thalassemia Gene Therapy
2021-11-23
FDA Approves First Interferon Therapy for Rare Blood Cancer
2021-11-15
LATEST
Bio Japan 2024 and Medical Japan 2024 Unleashing Innovation in Biopharmaceuticals and Healthcare Technologies
2024-10-07
Starboard Value Takes $1 Billion Stake in Pfizer, Eyes Major Overhaul
2024-10-07
Generative AI Makes its Debut in Smart Healthcare with NVIDIA Experts at the Helm
2024-10-04
How TCELS is Moving Thailand’s Biotech Industries From Local to Global
2024-10-04
Lilly Invests $4.5B in Indiana Facility for In-House Clinical Manufacturing
2024-10-03
Can New GLP-1 Contenders Disrupt the Weight-Loss Giants, Lilly and Novo, in the Battle for Market Dominance?
2024-10-03
2024 Tang Prize Celebrates Revolutionary Biopharma Discoveries, a Nod to Game-Changing Diabetes and Obesity Treatments
2024-09-30
EVENT
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
2024-10-28
BioFuture 2024
New York, U.S.A.
2024-10-30
AusBiotech 2024
Melbourne, Australia
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top